← Back to site

Last updated: April 23, 2026

Medical Treatment Consent

This Medical Treatment Consent describes the treatments available through the RENVA platform, their known risks and side effects, and your rights as a patient. By proceeding with your intake assessment, you acknowledge you have reviewed this information.

1. Consent to Treatment

By submitting your intake assessment on RENVA, you consent to the evaluation of your health information by a licensed independent clinician and — if clinically appropriate — the prescribing of one or more of the medications described in this document. Your assigned clinician retains sole clinical discretion over any prescribing decision.

No treatment will be initiated without a clinician review. You will be notified of the outcome of your clinical review before any prescription is transmitted to our pharmacy partner.

2. Prescribed Medications — Hair Loss

Finasteride (Oral)

Finasteride is an FDA-approved oral medication indicated for the treatment of male pattern hair loss (androgenetic alopecia) in men. It works by inhibiting the conversion of testosterone to dihydrotestosterone (DHT), the primary hormone responsible for follicle miniaturization.

Known side effects include:

  • Decreased libido, erectile dysfunction, or ejaculatory disorders (reported in a small percentage of users; may persist after discontinuation in rare cases).
  • Breast tenderness or enlargement (gynecomastia).
  • Depression or mood changes (rare).
  • Allergic reactions including rash, hives, or swelling (rare).
  • Finasteride is contraindicated in women who are or may become pregnant due to risk of birth defects.

Finasteride is prescribed for biological males only through the RENVA platform. If you are taking any medications metabolized by the liver or have a history of prostate issues, disclose this to your clinician before starting.

Minoxidil (Topical)

Minoxidil is an FDA-approved topical medication indicated for the treatment of hair loss (androgenetic alopecia) in both men and women. It promotes hair growth by prolonging the anagen (growth) phase of the hair follicle cycle.

Known side effects include:

  • Scalp irritation, dryness, flaking, or itching at the application site.
  • Unwanted facial or body hair growth in women.
  • Initial shedding in the first 2–8 weeks of use (temporary; indicates follicle cycling).
  • Rare cardiovascular effects (palpitations, fluid retention) — more common with oral minoxidil.
  • Allergic contact dermatitis (rare).

3. Prescribed Medications — Weight Loss

Semaglutide (Compounded Injectable)

Semaglutide is a GLP-1 receptor agonist used for chronic weight management. The compounded semaglutide dispensed through RENVA is prepared by a licensed compounding pharmacy and is not FDA-approved as a finished drug product. The active pharmaceutical ingredient (API) used meets USP standards.

Known side effects include:

  • Nausea, vomiting, diarrhea, constipation, and abdominal pain — most common during dose escalation.
  • Decreased appetite (generally desired in weight management).
  • Fatigue and headache.
  • Injection site reactions (redness, swelling, bruising).
  • Rare but serious: pancreatitis, gallbladder disease, hypoglycemia (especially with concurrent diabetes medications), and potential thyroid C-cell tumors (based on rodent studies; human risk unknown).

Semaglutide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Disclose all prior and current medications to your clinician before starting.

Tirzepatide (Compounded Injectable)

Tirzepatide is a dual GIP and GLP-1 receptor agonist used for chronic weight management. The compounded tirzepatide dispensed through RENVA is prepared by a licensed compounding pharmacy and is not FDA-approved as a finished drug product.

Known side effects include:

  • Nausea, vomiting, diarrhea, decreased appetite, constipation, and dyspepsia — most common during dose escalation.
  • Injection site reactions.
  • Fatigue, dizziness, and hair loss (temporary).
  • Rare but serious: pancreatitis, gallbladder disease, hypoglycemia, and potential thyroid C-cell effects (same caution as semaglutide).

Tirzepatide carries the same contraindications as semaglutide regarding thyroid history and MEN2.

4. Compounded Medications

Compounded medications dispensed through RENVA are prepared by state-licensed, FDA-registered compounding pharmacies. Compounded medications are not FDA-approved — they have not been evaluated by the FDA for safety, efficacy, or quality. Compounding is legal and common in medical practice, but you should be aware of this distinction before consenting to treatment.

5. No Guarantee of Results

Individual treatment outcomes vary. RENVA and the licensed clinicians in our network make no guarantees regarding the effectiveness of any prescribed medication. Hair regrowth, weight loss, and other outcomes depend on individual physiology, adherence to treatment, and other factors outside our control.

6. Duty to Disclose Health History Accurately

You have a legal and ethical obligation to provide your clinician with accurate, complete, and truthful health history information. Withholding or misrepresenting information — including current medications, allergies, medical conditions, or prior treatments — may result in inappropriate prescribing decisions that could harm your health. RENVA and the prescribing clinician bear no liability for outcomes arising from information you failed to disclose.

7. Right to Refuse Treatment

You have the right to refuse any recommended treatment, to ask questions about your treatment plan before consenting, and to discontinue treatment at any time. If you wish to stop a prescribed medication, notify your clinician through the RENVA platform before discontinuing, as some medications require a tapering protocol.

8. Questions

If you have questions about your treatment, prescribed medications, or side effects, message your clinician through the RENVA dashboard or contact us at darrin@renva.health.